Solventum
✦ Quant Fair Value how this is computed
- Implied fair-value range of 28.90-282.75, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -45.8% below the average-multiple fair value of 155.83.
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Solventum (SOLV) | 14.34B | 94.94 | 2.99 | 0.00% |
| Intuitive Surgical (ISRG) | 138.33B | 48.25 | 8.65 | 0.00% |
| Becton Dickinson & Co (BDX) | 57.96B | 52.02 | 2.35 | 1.97% |
| Alcon (ALC) | 35.92B | 54.24 | 1.64 | 0.48% |
| ResMed (RMD) | 33.14B | 21.46 | 5.57 | 1.04% |
| Medline (MDLN) | 32.55B | 57.52 | 2.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.3% above Morningstar's fair value estimate.
Analyst note
Solventum posted third-quarter results that included a 3% decline in organic sales and a 70-basis-point contraction in adjusted operating margin, as the firm prepares for the divestment of its health information systems segment.
Why it matters: Though Solventum's quarter was messy thanks to tariff refunds in the prior-year period and sales that were pulled forward earlier to avoid any disruption to customer orders while Solventum implemented a new ERP over the summer, the firm has made progress on its long-term goals. The separation from 3M is largely complete, and Solventum has renegotiated its supply agreement with its former parent. The former should lead to one-time spin costs rolling off, and the latter reduces risk around the supply chain.
The bottom line: We've raised our fair value estimate to $80 per share, up from $71, to reflect bottom-line progress, stronger-than-expected advanced wound care growth this year, and an updated share count. However, we remain reluctant to award Solventum a moat at this point. Its wound care and infection prevention businesses face relatively low switching costs. Nonetheless, there's still runway for Solventum to reshape its product portfolio and enhance operations so it can deliver profitability gains.
Big picture: CEO Bryan Hanson hasn't been shy about implementing strategic decisions around the product portfolio that 3M divested. We applauded the decision to jettison the lower-margin purification and filtration business last year. We also favor the upcoming divestment of Solventum's health information systems, which largely sits in a subscale position in a consolidating category. The firm has indicated it would use some proceeds from the divestment to pay down debt, which could put Solventum in a stronger position to make some tuck-in acquisitions in the midterm.
Fair value
We've boosted our fair value estimate of $80 per share, up from $71, reflecting recent strength in advanced wound care and an updated share count. We assume the firm can maintain organic low-single-digit revenue growth through 2030, reflecting Solventum’s portfolio that skews toward mature markets. While Solventum has indicated it plans to shift the product portfolio to focus on faster-growing products to accelerate consolidated growth, we’re holding off on giving it any credit for this until we see some hints of success in medsurg and dental.
As management reorganizes and generates efficiencies, we estimate gross margin can improve by roughly 350 basis points as the firm rationalizes its sourcing and production footprint and sheds the purification and filtration business. We also project selling, general, and administrative expense as a percentage of sales to decline by 350 basis points through our explicit forecast period. Conversely, we anticipate the firm will need to incrementally raise research and development investment as a percentage of sales by roughly 100 basis points through the midterm to support Solventum’s aim to generate more innovation. This translates into consolidated operating margin hitting 14.5% at the end of our explicit forecast period, up significantly from 7.6% in 2025, but not far from 12.5% seen in 2024. We estimate Solventum’s cost of capital at 7.4%, which incorporates a 9% cost of equity.
Economic moat
We think Solventum has yet to dig a moat around its business. Though returns on invested capital for the healthcare segment remained over the cost of capital while this entity was still housed within 3M, the path forward will be more challenging as the new costs of operating as an independent company and debt service for newly acquired debt weigh on returns.
While Solventum is a sizable competitor in advanced wound care, we don’t see many sources of moat in this market. Indeed, we’ve long viewed the category of foams and silver antibacterial and hydrocolloidal dressings as vulnerable to low switching costs. As a result, we have not awarded moats for the wound care business at any of Solventum’s direct competitors in AWC, including Smith & Nephew, Convatec, and Coloplast (though these rivals may sport moats derived from other businesses).
Most advanced wound products are not protected by intellectual property, and few manufacturers invest in clinical trials to help differentiate products on efficacy. This has laid the groundwork for companies to compete on the basis of marketing, detailing of wound care nurses, and persuading group purchasing organizations to carry their AWC products on their formularies. It’s not clear that Solventum’s brands of AWC are viewed as superior to those of its key competitors.
We note that, unlike highly engineered physician preference items such as pacemakers and knee implants, most advanced wound care products are more commoditized and are sold mainly through a consolidated set of GPOs. This means the AWC manufacturers face more price pressure in negotiating with the GPOs.
Solventum’s primary strategy for expanding its AWC business is through its negative-pressure wound therapy devices. While this niche in advanced wound care holds some potential because the competitive field is largely a duopoly between Solventum and Smith & Nephew, the clinical data to support its efficacy has been slow to come. Additionally, NPWT is relatively expensive compared with most other engineered dressings. For this reason, the Centers for Medicare & Medicaid Services cracked down on coding and reimbursement for NPWT from 2006 through 2016, significantly reducing payments for the core vacuum machine and corresponding consumables.
Since then, NPWT devices have evolved into single-use, disposable items that have managed to raise reimbursement rates, but we remain wary that the CMS could lower rates again unilaterally.
Solventum recently acquired Acera Surgical, which gives it entry into the most dynamic and fast-growing niche in advanced wound care, skin substitutes. This area has faced major cuts to previously generous reimbursement at CMS. However, the CMS cuts were aimed at the use of skin substitutes for chronic wound care. Smith & Nephew, Convatec, and Coloplast all have various skin substitutes, from placenta-based products to fish skin, that were exposed to these payment reductions. Acera's synthetic products are largely used in the acute care setting, which means it has dodged this round of cuts.
Perhaps more concerning, if the favorable early clinical data on these skin substitutes is borne out in large-scale studies, we think this category could pose a significant threat to NPWT. Thus far, small-scale studies have suggested that fish skin and placenta-based wound therapy is surprisingly efficacious on hard-to-heal wounds such as diabetic foot ulcers. This could cut into demand for NPWT, or relegate it to acute wound care, while expensive-to-treat chronic wounds migrate to these skin substitutes.
Solventum’s dental business is mainly driven by its resin composite business for fillings and secondarily by its orthodontic clear aligners. While margins on this business are currently healthy, it is difficult for us to see how Solventum will be able to defend its price over the longer term when barriers to entry are so low and there are already a number of competitors offering comparable composites. On the orthodontic side, we already see low-cost new entrants like SmileSet. For instance, the typical cost of treatment with Solventum’s Clarity clear aligners is $2,500-$4,500, depending on the complexity of the malocclusion. For SmileSet, the recently promoted price was roughly $1,500.
Unlike Align Technology, which enjoys a narrow moat as the overwhelming market leader in clear aligners with a known brand, we don’t think Solventum likely has as large a database of cases on which to base its models. Align also benefits from switching costs associated with its iTero scanner, which is integrated with its aligner platform. Solventum doesn’t offer that type of closed ecosystem.
On the whole, we view Solventum’s environmental, social, and governance risk as low. The most material ESG risk is related to product governance, though Solventum’s products generally don’t fall in the category of life-saving or life-sustaining. For this reason, we think Solventum has lower exposure to product governance risk than device makers that offer implantable hardware.
Bull case
CEO Bryan Hanson and CFO Wayde McMillan are both highly seasoned leaders with solid records at Covidien, Medtronic, Zimmer Biomet, and Insulet.
We think Solventum’s health information systems business, while relatively small, could retain clients through high switching costs, like other software firms.
We think there are relatively near-term, high-impact actions management can take to rachet up operations and profitability.
Bear case
Many of Solventum’s medsurg products are sold to group purchasing organizations, where there is more price pressure than with highly engineered physician preference items marketed directly to doctors.
We think it will be challenging to create a moat around Solventum’s advanced wound care business, as switching costs are relatively low.
The jury is still out on whether Solventum can roll out innovative products that can secure price premiums. While we’ve seen this happen at C.R. Bard, we remain skeptical about Solventum’s products.
By Debbie S. Wang
Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.
Solventum discussion 0 comments